DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...
DXCM looks poised for growth as CGM demand expands, G7 and One+ adoption accelerates, and strong Q4 results support a hold ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
Medical device company DexCom (NASDAQ:DXCM) announced in Q3 CY2025, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to ...
Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...
DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback